Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Yuki TahataHayato HikitaSatoshi MochidaNorifumi KawadaNobuyuki EnomotoAkio IdoHitoshi YoshijiDaiki MikiYoichi HiasaYasuhiro TakikawaRyotaro SakamoriMasayuki KurosakiHiroshi YatsuhashiRyosuke TateishiYoshiyuki UenoYoshito ItohTaro YamashitaTatsuya KantoGoki SudaYasunari NakamotoNaoya KatoYasuhiro AsahinaKentaro MatsuuraShuji TeraiKazuhiko NakaoMasahito ShimizuTaro TakamiNorio AkutaRyoko YamadaTakahiro KodamaTomohide TatsumiTomomi YamadaTetsuo TakeharaPublished in: Journal of gastroenterology (2020)
Real-world efficacy of SOF/VEL treatment for patients with decompensated cirrhosis was similar to Japanese phase 3 study, although treatment discontinuation and death related to liver disease occurred. In patients with poor hepatic reserve, whether it improves continuously after viral clearance requires further evaluation.